Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
暂无分享,去创建一个
S. Pileri | R. Fanin | A. Levis | E. Sabattini | Alessandria | A. Vacca | R. Ria | U. Vitolo | A. Tucci | E. Brusamolino | F. Zaja | M. Balzarotti | S. Volpetti | C. Rusconi | C. Monagheddu | F. Salvi | C. Bottelli | L. Orsucci | S. De Luca | M. Bonfichi | E. Ravelli | A. Vacca | Di Rocco | Bottelli C | Balzarotti M Brusamolino | Bonfichi M | Pileri Sa | Sabattini E | Volpetti S | Monagheddu C | Vacca A | Ria R | Fanin R | Ao Ss Antonio E Biagio | C. Arrigo | S. Pileri | Stefano De Luca | Chiara Monagheddu
[1] J. Vose,et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Michael L. Wang,et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. , 2011, Leukemia research.
[3] J. Kosek,et al. Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation. , 2010 .
[4] P. Schafer,et al. Treatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing. , 2009 .
[5] J. Vose,et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Worland,et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. , 2009, Cancer research.
[7] I. Lossos,et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma , 2009, British journal of haematology.
[8] E. Hoster,et al. Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] I. Lossos,et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[11] E. Campo,et al. Advances in the understanding of mantle cell lymphoma , 2008, British journal of haematology.
[12] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[13] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[14] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Jagannath,et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.
[16] N. Munshi,et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. , 2004, Blood.
[17] D. Weisenburger,et al. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.